Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]
In development
Reference number: GID-TA11232
Expected publication date:
Due to operational constaints at NICE although the topic remains a single technology appraisal (STA) it will be discussed by the highly specialised technologies (HST) committee in on 19 June 2025.